Cardiac involvement and clinical follow up of patients with hereditary transthyretin related amyloidosis associated with Glu89Gln mutation by unknown
POSTER PRESENTATION Open Access
Cardiac involvement and clinical follow up of
patients with hereditary transthyretin related
amyloidosis associated with Glu89Gln mutation
Mariana Gospodinova1*, Stayko Sarafov2, Velina Guergueltcheva3, Andrey Kirov4, Teodora Chamova2,
Albena Todorova4, Ivailo Tournev2, Stefan Denchev1
From First European Congress on Hereditary ATTR amyloidosis
Paris, France. 2-3 November 2015
Background
Cardiac involvement is common in hereditary transthyr-
etin – related amyloidosis (ATTR), but there is a signifi-
cant phenotypic heterogeneity depending on the
mutation.
Patients and methods
We evaluated forty consecutive ATTR patients with
Glu89Gln mutation, focusing on cardiac involvement - 18
male, 22 female at a mean age of 57.6±6,7 years. A clinical
examination, 12–channel ECG, conventional 2D, Doppler
and tissue Doppler echocardiography were performed.
The patients were followed for 36 months in the range
from 2 to 78 months.
Results
Median age of symptoms development was 52, 3±6, 4
years. Cardiac onset was found in 5 (12,5%) patients.
Cardiomyopathy and peripheral polyneuropathy were
evident at diagnosis in all patients. Echocardiography
revealed a significant increase in wall thickness of both
left and right ventricles (septum – 18,6±3,4 mm; pos-
terior wall – 17,5±2,5 mm; RV free wall – 8,4±2,0
mm). Varying degrees of LV diastolic dysfunction were
found – Grade 1 in 11 (27,5%) patients, Grade 2 in 12
(30%) and Grade 3 in 17 (42,5%) patients. A reduced
LV ejection fraction was found in 9 (22,5%) patients. A
common finding were significantly reduced mitral
annular systolic velocities (s´septum-5,4±2,0 cm/s, s
lat.-5,7±1,9 cm/s), registered in all the evaluated
patients, pointing to an impaired LV longitudinal
systolic function. The systolic myocardial velocities of
the tricuspid annulus and TAPSE values were reduced
respectively 6,9±2,1cm/s and 12,8±3 mm in 14 of the
patients (35%). Pericardial effusion was found in
13 (32,5%) patients.
Pathological ECG was present in 35(87,5%) of the
evaluated patients. Atrial fibrillation was registered in
4 (10%) patients, A-V block first degree in 8 (20%), low
voltage in 15 (37,5%), left bundle branch block in
3 (7,5%), left anterior fascicular block in 9 (22,5%),
pathological Q wave in 14 (35%), right bundle branch
block in 2 (5%), and pace-maker rhythm in 2 (5%).
Rhythm and conduction disturbances on ECG were
found in 24 patients (60%).
The following events occurred during the follow-up
period: two deaths (5,4%) (one patient due to ischemic
stroke; and another due to heart failure). Two other
patients suffered from ischemic strokes. 24-hour Holter
ECG revealed short periods of atrial fibrillation and an
oral anticoagulant was initiated. A sinus pause > 3 s was
observed in one of the patients and a permanent pace-
maker was implanted. Four new cases (10%) with symp-
tomatic heart failure, requiring diuretic treatment were
observed. In 15 patients a worsening of the symptoms
from the peripheral neuropathy were found.
Conclusion
Our study confirms that ATTR associated with the
Glu89Gln mutation has a mixed phenotype – neurological
and cardiac and an unfavorable prognosis. Our findings
imply that patients and carriers of Glu89Gln require close
multidisciplinary (both cardiological and neurological) fol-
low-up in order to initiate treatment in time.
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